FDA approves first drug to treat hallucinations in Parkinson’s psychosis

Pimavanserin on April 29 became the first drug to receive approval from the Food and Drug Administration for the indication of hallucinations and delusions associated with psychosis in Parkinson’s...
Source: Clinical Neurology News - Category: Neurology Source Type: news